Please login to the form below

Not currently logged in

Amgen's Mvasi is first FDA-approved cancer biosimilar

Amgen flag

Offers prospect of lower-cost alternative to Roche's Avastin

Sandoz says Humira biosimilar clears clinical hurdle

Sandoz NovartisIts drug matches the safety and efficacy of AbbVie’s plaque psoriasis blockbuster

Lilly's abemaciclib data leaves potential uncertain

Eli Lilly HQMONARCH 3 trial showed similar results to Pfizer’s Ibrance and Novartis’ Kisqali

Novartis scores but Roche misses in melanoma trials

Novartis buildingPhase III trial combo success for Tafinlar/Mekinist “unprecedented”

Teva poaches Lundbeck's Schultz as new CEO

TevaShares in Lundbeck fall as two senior posts become vacant

Prix Galien opens for entries with new award

UK Prix Galien Awards 20122018 programme will include new medical technology category

AZ buoyed by latest lung cancer data at ESMO

ESMOData from separate Tagrisso and Imfinzi trials show superior PFS among patients

Lilly axes 3,500 jobs in $500m-a-year cost-cutting drive

Eli Lilly HQUS drug maker to slash its workforce by 8.5%

BMS' Opdivo and Yervoy ace kidney cancer trial

Bristol-Myers Squibb (BMS) buildingCombined checkpoint inhibitors show improved survival versus standard therapy

Riding the wave of digital disruption

The challenges and rewards of meeting consumer expectations

  • Real-world evidence

    Companies are now recruiting high-level executives to lead well-resourced RWE teams as industry looks to reshape the future

  • The future of biotech

    What impact will the sector, and its R&D performance, have on pharma?

Featured jobs

Subscribe to our email news alerts


Add my company

Our higher purpose is to deliver better communication to increase and speed up the ability of patients to access better...

Latest intelligence

Biosimilars: what the future looks like
Biosimilars: what the future looks like...
Tightening medical device safety
European legislators seek to reduce patient exposure to safety risks...
Research Partnership has published a new Living with Ulcerative Colitis (UC) US market report for 2017